Patents Examined by Howard E. Schain
  • Process for producing regenerated collagen fiber
    Patent number: 5344917
    Abstract: A process for producing regenerated collagen fiber from solubilized collagen including adjusting a degree of swelling of solubilized collagen to 100 to 300% and then treating the resulting solubilized collagen with an aqueous solution of a metallic salt. The regenerated collagen fiber has excellent water resistance and undergoes no waving on contact with water.
    Type: Grant
    Filed: December 28, 1992
    Date of Patent: September 6, 1994
    Assignee: Kanegafuchi Kagaku Kogyo Kabushiki Kaisha
    Inventors: Mitsuru Furukawa, Masahiko Takada, Shoichi Murata, Atsushi Sasayama
  • Process for the manufacture of a high-purity activated factor VII concentrate essentially free of vitamin K-dependent factors and factors VIIIC and VIIICAg
    Patent number: 5344918
    Abstract: The invention relates to a process for the manufacture of a high-purity activated factor VII concentrate.This process comprises the use of a plasma free of cryoprecipitate, preferably of human origin, as well as at least one purification step involving chromatography at least once on an ion exchange resin, and a factor VII activation step, wherein the first stage is direct activation of the factor VII in the crude supernatant of plasma free of cryoprecipitate, without the addition of exogenous proteins.By virtue of the invention, the high-purity activated factor VII is essentially free of vitamin K-dependent factors and factors VIIIC and VIIICAg and has a factor VIIa/factor VII ratio greater than 5 with a specific activity of the activated factor VII greater than 200 IU/mg of proteins.
    Type: Grant
    Filed: December 10, 1992
    Date of Patent: September 6, 1994
    Assignee: Association d'Aquitaine pour le Developpement de la Transfusion Sanguine et des Recherches Hematologiques
    Inventors: Bernard Dazey, Mohamed Hamsany, Sylvia Enfedaque-Morer
  • Process for refining zein
    Patent number: 5342923
    Abstract: There is disclosed a process for refining a zein. A solution containing crude zein, as a raw material is finely dispersed into absolute or high purity acetone solution having no ability for dissolving the zein, to cause precipitation of a zein component, as porous solids.
    Type: Grant
    Filed: April 28, 1992
    Date of Patent: August 30, 1994
    Assignee: Showa Sangyo Co., Ltd.
    Inventors: Hidekazu Takahashi, Norimasa Yanai
  • Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
    Patent number: 5334705
    Abstract: The invention is directed to a low oxygen affinity stroma-free tetrameric mammalian hemoglobin which is produced by crosslinkng with a derivative of benzenetricarboxylate, as well as methods for its preparation. Crosslinked stroma-free hemoglobin produced by methods of the present invention may be used in applications requiring physiological oxygen carriers such as in blood substitute solutions, or as in a plasma expander.
    Type: Grant
    Filed: August 15, 1991
    Date of Patent: August 2, 1994
    Assignee: Duke University
    Inventors: Joseph Bonaventura, Marius Brouwer, Robert E. Cashon
  • Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
    Patent number: 5334380
    Abstract: Methods and compositions for treating and inhibiting hypotension related to both endotoxin and cytokine-induced shock are provided. A therapeutic regimen useful in the present invention includes an arginine-free parenteral formulation administered with or followed by the administration of an anti-endotoxin antibody, an interleukin-1 or interleukin-2 receptor antagonist, an anti-tumor necrosis factor antibody or a combination thereof. Most preferably, the administration of an arginine-free parenteral formulation augments the anti-hypotensive effect of the various antibodies and antagonist described so as to provide an effective treatment for various forms of hypotension. The therapeutic regimens of the invention are proposed to provide for a decrease in nitric oxide synthase, and thereby an increase in blood pressure in vivo, particularly in animals with cytokine- and/or endotoxin-induced hypotension.
    Type: Grant
    Filed: June 30, 1992
    Date of Patent: August 2, 1994
    Assignee: Board of Regents, The University of Texas System
    Inventors: Robert G. Kilbourn, Owen W. Griffith, Steven S. Gross
  • Method of impeding apoptosis of CD4 cells in persons infected with human immunodeficiency virus
    Patent number: 5330972
    Abstract: The apoptosis of CD4 cells in a person infected with the human immunodeficiency virus may be impeded by enterally feeding to the infected person a nutritional product which contains soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30%-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact protein. The nutritional product has a ratio, by weight, of n-6 to n-3 fatty acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: July 19, 1994
    Assignee: Abbott Laboratories
    Inventor: Frederick O. Cope
  • Homogeneous erythropoietin compositions and methods of using same
    Patent number: 5322837
    Abstract: A method for purifying erythropoietin is described. The method comprises treating partially purifying erythropoietin by reverse phase high performance liquid chromatography to obtain homogeneous erythropoietin having a molecular weight of about 34,000 daltons on SDS PAGE and moving a single peak on reverse phase HPLC. The homogeneous erythropoietin protein preferably has a specific activity of at least 120,000 IU, more preferably at least 160,000 IU per absorbance unit at 280 nm.
    Type: Grant
    Filed: July 31, 1992
    Date of Patent: June 21, 1994
    Assignee: Genetics Institute, Inc.
    Inventors: Rodney M. Hewick, Jasbir S. Seenra
  • Process for large-scale production of antimicrobal peptide in high purity
    Patent number: 5317084
    Abstract: Lactoferricin (Trade Mark), also called LFCIN (Trade Mark), a potent antimicrobial peptide, is produced by contacting an enzymatic hydrolysate of bovine lactoferrin or any mixture of peptides containing lactoferricin preferably with a butyl moiety-containing hydrophobic interaction chromatography medium, or alternatively with a carboxymethyl moiety-containing cation-exchange chromatography medium, rinsing the medium to remove unbound peptides, desorbing the lactoferricin solution at constant pH, and desalting the desorbed solution. The utility of the process is illustrated, for example, as follows. An enzymatic hydrolysate of bovine lactoferrin (600 g) was contacted with 3000 ml of BUTYL-TOYOPEARL 650M, the medium was rinsed with water, and then with McIlvaine (citric acid-sodium phosphate) buffer at pH 7.0., and lactoferricin was desorbed with McIlvaine buffer at pH 5.0.
    Type: Grant
    Filed: May 29, 1992
    Date of Patent: May 31, 1994
    Assignee: Morinaga Milk Industry Co., Ltd.
    Inventors: Mamoru Tomita, Seiichi Shimamura, Kozo Kawase, Yasuo Fukuwatari, Mitsunori Takase, Wayne Bellamy, Tomoyuki Hagiwara, Hiroyuki Matukuma
  • Intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen
    Patent number: 5314874
    Abstract: The present invention provides an intracorporeally injectable non-toxic composition of atelocollagen having an excellent, long-lasting skin swelling effect due to its low viscosity, good fluidity, easy injectability and low antigenicity (without calcification) properties. The composition is prepared by treating an aqueous suspension of atelocollagen with a buffer for physiological conditions. The suspension can have atelocollagen content of 55 to 75 mg/ml, where approximately 20 to 100% by weight of atelocollagen is cross-linked with a polyepoxy compound.
    Type: Grant
    Filed: April 15, 1992
    Date of Patent: May 24, 1994
    Assignee: Koken Co., Ltd.
    Inventors: Teruo Miyata, Tadatomo Kawai
  • Pharmaceutical composition of stabilized [Leu.sup.13 ]-motilin-Hse
    Patent number: 5308836
    Abstract: There is disclosed a pharmaceutical composition of stabilized [Leu.sup.13 ]-motilin-Hse. The composition comprises at least one of organic acids and salts thereof, as a first stabilizer, and pH thereof is adjusted in a range of 5.5-8.0. The composition may contain at least one of substances selected from saccharides, amino acids, proteins and salts thereof, as a second stabilizer. Conversion of [Leu.sup.13 ]-motilin-Hse into [Leu.sup.13 ]-motilin-Hse-lactone is suppressed by increasing pH value and deamidization in asparagine residue at 19-position is suppressed by the presence of the organic acid or salt thereof.
    Type: Grant
    Filed: September 7, 1993
    Date of Patent: May 3, 1994
    Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.
    Inventors: Kiichi Sawai, Masayasu Kurono, Yasuaki Kondo, Makoto Sato, Toshiyuki Kouzaki
  • Nutritional product for persons having a neurological injury
    Patent number: 5308832
    Abstract: An enteral nutritional product for a person having a neurological injury is very low in carbohydrate, but high in fat. The fat is supplied by a lipid blend having a ratio of n-6 to n-3 fatty acids in the range of 1 to 6. Preferably the nutritional product contains nutrients having antioxidant properties, for example beta-carotene, vitamin E, vitamin C, taurine, molybdenum and selenium.
    Type: Grant
    Filed: July 27, 1992
    Date of Patent: May 3, 1994
    Assignee: Abbott Laboratories
    Inventors: Keith A. Garleb, Stephen J. DeMichele, Linda S. Rausch, Martha K. Fuller, Stephen R. Behr
  • Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
    Patent number: 5306709
    Abstract: Macrophage inflammatory protein-1 or -2, or analog thereof, is administered to a mammal to achieve therapeutic reduction of the number of circulating platelets. The proteins are useful in treating essential thrombocythemia and reactive thrombocytosis.
    Type: Grant
    Filed: November 15, 1991
    Date of Patent: April 26, 1994
    Assignee: The University of Pennsylvania
    Inventor: Alan M. Gewirtz
  • Anticoagulant substance obtained from urine
    Patent number: 5300490
    Abstract: This invention relates to a novel anticoagulant substance in human urine, a process for its preparation and a pharmaceutical composition comprising the said substance for the prevention and/or treatment of diseases related to the disorders in blood coagulation system.
    Type: Grant
    Filed: August 20, 1992
    Date of Patent: April 5, 1994
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Yasuyuki Kunihiro, Ryo Tanaka, Michio Ichimura, Akio Uemura, Nobuo Ohzawa, Ei Mochida
  • Composition and method for treating inflammation
    Patent number: 5300292
    Abstract: A method for treatment of inflammation, comprising the step of administering to a patient in need thereof an effective, inflammation-inhibiting amount of a composition comprising IL-6, or IL-6 and TGF.beta. together in a weight ratio of from about 5:95 to 95:5, preferably from about 20:80 to 80:20. Also disclosed is a composition for treatment of inflammation, comprising as active ingredients IL-6 and TGF.beta. in a weight ratio of from about 5:95 to about 95:5, optionally comprising a carrier in combination with the active ingredients, and a method of reducing migration of neutrophils into tissue of an animal which has received an inflammatory stimulus, comprising the step of administering to the tissue an effective neutrophil-migration-inhibiting amount of a composition as defined above.
    Type: Grant
    Filed: December 10, 1992
    Date of Patent: April 5, 1994
    Assignee: The Regents of the University of California
    Inventor: Thomas R. Ulich
  • Compound for use in dietetics, reanimation and therapeutics containing protein fractions based on three types of minipeptides
    Patent number: 5298493
    Abstract: Methods of treating patients with new compositions intended for use in dietetics, reanimation and therapeutics are provided. The new compositions contain a protein fraction based on three types of minipeptides. The method involves the step of administering a therapeutically effective amount of a composition including specific minipeptides including casein minipeptides with and without phosphopeptides wherein the quantity of selected minipeptides is chosen to assure a proper balance between the sulfur containing amino acids and phosphors bound to proteins.
    Type: Grant
    Filed: February 5, 1993
    Date of Patent: March 29, 1994
    Assignee: Clintec Nutrition Co.
    Inventor: Francois Mendy
  • Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes
    Patent number: 5298604
    Abstract: Electrophoretically homogeneous human Antineoplastic Urinary Protein (ANUP) contains a blocked N-terminal amino acid that has been identified as pyroglutamic acid. Removal of the pyroglutamy residue by the use of pyroglutamyl aminopeptidose results in the formation of the deblocked protein which is also an antineoplastic molecule. The amino acid sequence of the deblocked ANUP 16 KD monomer showed the following sequence:Cycle No.1. Leu L2. Lys K3. Cys C4. Tyr Y5. Thr T6. Cys C7. Lys K8. Glu E9. Pro P10. Met MCycle No.11. Thr T12. Thr (T)? or Ser (S)?13. Ala A14. Ala A15. X?A data base search using the above sequence showed that 100% homology with another protein was not found regardless of unassigned positions.The blocked N-terminal amino acid of ANUP is pyroglutamic acid.
    Type: Grant
    Filed: September 2, 1993
    Date of Patent: March 29, 1994
    Inventor: Nathan H. Sloane
  • Inhibition of coloration of human serum albumin
    Patent number: 5294699
    Abstract: A method of inhibiting the coloration of human serum albumin expressed by using the gene manipulation technology which method comprises separating coloring contaminants from said human serum albumin before said coloring contaminants bind to the human serum albumin.
    Type: Grant
    Filed: June 24, 1991
    Date of Patent: March 15, 1994
    Assignee: The Green Cross Corporation
    Inventors: Takao Ohmura, Akinori Sumi, Wataru Ohtani, Naoto Fuluhata, Kaoru Kobayashi, Shinobu Kuwae, Hirotoshi Fukutsuka, Tomoshi Ohya, Hiroshi Morise
  • Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
    Patent number: 5292869
    Abstract: The present invention relates to a method for isolating and purifying transferrin and lactoferrin receptor proteins from bacterial pathogens by affinity chromatography and to the preparation of vaccine antigens containing the purified receptor proteins.
    Type: Grant
    Filed: April 11, 1990
    Date of Patent: March 8, 1994
    Assignee: The Board of Governors of the University
    Inventor: Anthony B. Schryvers
  • Placenta-derived coagulation inhibitor
    Patent number: 5290915
    Abstract: A monoclonal antibody specific to a human placenta-derived coagulation inhibitor is disclosed. The antibody is produced by culturing a hybridoma which secretes it. A human placenta-derived coagulation inhibitor can be purified by using the monoclonal antibody as an immunoadsorbent. The human placenta-derived coagulation inhibitor can be immunologically assayed by using the monoclonal antibodies.
    Type: Grant
    Filed: January 13, 1992
    Date of Patent: March 1, 1994
    Assignee: Kowa Co., Ltd.
    Inventors: Hiroshi Nakao, Takao Nagoya, Yushi Saino, Masahiro Maki, Hideo Tani
  • Method of treating asthma using IL-8
    Patent number: 5290550
    Abstract: A method of treating asthma in a subject in need of such treatment comprises contacting Interleukin-8 or an active fragment thereof to the respiratory epithelium of the subject. The active agent is preferably human endothelial IL-8, and is preferably contacted to the subject's respiratory epithelium by causing the subject to inhale respirable particles comprised of the active agent.
    Type: Grant
    Filed: June 7, 1993
    Date of Patent: March 1, 1994
    Assignee: East Carolina University
    Inventors: Robert H. Fisher, W. James Metzger